In adults with acute VTE, apixaban vs. rivaroxaban reduced clinically relevant bleeding at 3 mo

Key Points

• This study aims to compare the efficacy of apixaban and rivaroxaban in reducing clinically relevant bleeding in adults with acute venous thromboembolism (VTE).
• Randomized trial design
• Participants were adults diagnosed with acute VTE
• Comparison of clinical bleeding rates at 3 months between apixaban and rivaroxaban
• The incidence of clinically relevant bleeding was lower in the apixaban group compared to the rivaroxaban group (specific rates not provided).
• No significant difference in VTE recurrence was noted between treatment groups.
• Apixaban showed a better safety profile regarding bleeding complications compared to rivaroxaban.